Antioxidants as Complementary Medication in Thalassemia

Srichairatanakool, Somdet; Fucharoen, Suthat

doi:10.5772/57372

Cited by 5 publications

(5 citation statements)

References 174 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SCD subjects the protective role of HU therapy was reported to be more pronounced in patients receiving HU along with iron chelation therapy as compared to HU therapy alone . Use of antioxidants as complementary medicine in β‐thalassemia is advocated by clinicians . Our study group, however, indicated higher concentrations of ferritin in all patients (treated/untreated), suggesting an inadequate use of iron chelation therapy.…”

Section: Discussioncontrasting

confidence: 52%

Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy inβ-Thalassemia Patients

Zohaib

Ansari

Hashim

et al. 2015

The Journal of Clinical Pharmacology

View full text Add to dashboard Cite

β-Thalassemia is the most common hereditary disorder characterized by reduced production of β-globin chains of hemoglobin A (HbA). In recent years, hydroxyurea (HU) has shown promising therapeutic benefits in patients with β-thalassemia by fetal hemoglobin augmentation. We have analyzed effects of hydroxyurea treatment on oxidative stress in β-thalassemia patients by assessing activities of paraoxonase (PON) and arylesterase along with malondialdehyde (MDA) and total reactive oxygen species (ROS) concentrations. Blood samples from 159 individuals including 56 HU-treated and 58 untreated β-thalassemia patients and 45 healthy controls were analyzed. PON activity was found to be highest in healthy individuals (177.76 ± 4.44 U/mL) as compared to treated (52.67 ± 3.65 U/mL) and untreated (55.11 ± 3.26 U/mL) patients. A similar trend was observed in the case of arylesterase activity in normal, β-thalassemia-treated, and untreated (210.0 ± 11.25 U/mL, 163.03 ± 9.04 U/mL, 139.77 ± 10.10 U/mL) subjects. Serum MDA concentrations (2.59 ± 0.09 nmol/mL, 2.45 ± 0.08 nmol/mL, and 1.15 ± 0.05 nmol/mL) and total ROS concentrations (3.73 ± 0.20 nmol/mL, 3.54 ± 0.23 nmol/mL, and 2.45 ± 0.14 nmol/mL) were significantly elevated in both groups (untreated and treated) as compared to healthy individuals (P < .01). Oxidative stress was found to be markedly elevated in β-thalassemia patients as compared to healthy controls. Insignificant differences were, however, observed in mean concentrations of PON1 paraoxonase and arylesterase activities, serum MDA concentration and total ROS concentrations between HU-treated and untreated patients. We propose that HU therapy alone seems to be ineffective in managing oxidative stress and is likely to offer a better clinical outcome when supplemented with efficient iron chelation therapy and antioxidants.

show abstract

Section: Discussioncontrasting

confidence: 52%

Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy inβ-Thalassemia Patients

Zohaib

Ansari

Hashim

et al. 2015

The Journal of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

“…We found that white meat consumption in TDT patients was less than control subjects, as far as frequency of consumption of meat per week is concerned . We found that majority of TDT patients were consuming 1-2 times per week followed by 3-4 times per week, which was comparatively higher consumption than control subjects, [16] also reported that adult thalassemia patients consumed sufficient amount of meat and vegetables which comparable with present study observed that majority of the TDT patients were consuming 5-8 cups per week as compared to control subjects. Higher consumption of tea and milk is reported to be beneficial in TDT patients because it reduces iron absorption as the TDT patients are already iron overloaded due to transfusion [17].…”

Section: Resultssupporting

confidence: 87%

Blood Chemistry (Hematology)of Transfusion Dependent Beta Thalassemia Patients at Hyderabad and Adjoining Areas

Solangi

Channa

Memon³

et al. 2018

Pak. J. Anal. Environ. Chem

View full text Add to dashboard Cite

Present study was carried out to analyze quantitatively the blood parameters of Transfusion Dependent Thalassemia (TDT) patients. A total number of seventy one (n=71) TDT patients aged 04 to 26 years were selected from Fatimid foundation center, Hyderabad from June 2015 to May 2016 and eighty four (n=84) control subjects (age, gender and locality matched persons with negative personal and family history of thalassemia) were included in this study. Blood sample of 5mL was collected from each participant to analyze white blood cells (WBC); total leukocytes counts (TLC); red blood cells (RBC); mean corpuscular value (MCV); mean corpuscular hemoglobin (MCH); mean corpuscular hemoglobin concentration (MCHC); hemoglobin (HB) and hematocrit (HCT). All the patients and control subjects were interviewed through a standard questionnaire specially developed to study their life style and dietary habits. The collected data from TDT patients and control subjects was statistically analyzed by using p<0.05 as statistically significant variation between two groups. Results revealed significantly decreased levels of HCT, MCV, MCH and platelets in TDT patients as compared to control subjects. All TDT patients were frequently undergoing blood transfusion within the age groups.

show abstract

“…It has been reported that supplements of the antioxidant compounds (vitamins C and E, selenium, and zinc) can prevent some of the damage in the thalassemic red blood cell membrane and ameliorate pathophysiological complications [42,74]. Recently, Yanpanitch et al [75] investigated the effects of antioxidant cocktails for the treatment of β-thalassemia/hemoglobin E (HbE), which is the most common form of β-thalassemia in Southeast Asia.…”

Section: Discussionmentioning

confidence: 99%

Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major

et al. 2017

View full text Add to dashboard Cite

Background: Ischemia-modified albumin (IMA) is an altered type of serum albumin that forms under conditions of oxidative stress and an independent predictor of major adverse cardiovascular events. Objectives: To measure the levels of IMA in 45 children and adolescents with β-thalassemia major (β-TM) compared with 30 healthy controls and assess its relation to lipid peroxidation, vascular complications and subclinical atherosclerosis. Methods: β-TM patients without symptoms of heart disease were studied focusing on transfusion history, chelation therapy, serum ferritin, malondialdehyde (MDA) and IMA levels. Echocardiography was performed and carotid intima media thickness (CIMT) was assessed. Results: IMA and MDA levels were significantly higher in β-TM patients compared with controls (p < 0.001). IMA was higher among patients with heart disease, pulmonary hypertension risk and serum ferritin ≥2500 µg/l than those without. TM patients compliant to chelation had significantly lower IMA levels. IMA levels were positively correlated to MDA and CIMT while negatively correlated to ejection fraction and fractional shortening. Conclusion: Our results highlight the role of oxidative stress in the pathophysiology of vascular complications in thalassemia. IMA could be useful for screening of β-TM patients at risk of cardiopulmonary complications and atherosclerosis because its alteration occurs in early subclinical disease.

show abstract

Antioxidants as Complementary Medication in Thalassemia

Cited by 5 publications

References 174 publications

Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy inβ-Thalassemia Patients

Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy inβ-Thalassemia Patients

Blood Chemistry (Hematology)of Transfusion Dependent Beta Thalassemia Patients at Hyderabad and Adjoining Areas

Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major

Contact Info

Product

Resources

About